Ftse Mib
33.629,21
-0,32%
DAX
18.001,60
0,54%
S&P 500
5.127,79
1,26%
NASDAQ
16.156,33
1,99%
Bitcoin
63.494,93
0,96%

Quotazioni in diretta

Non abbiamo trovato risultati per:
Assicurati di aver scritto correttamente o prova ad allargare la ricerca.

Più Attivi

Toplist

Sembra che tu non sia connesso.
Clicca il pulsante qui sotto per accedere e visualizzare la tua cronologia recente.

Registrati

Sei già registrato? Accedi

Pepperstone

Inizia Ora

Pepperstone
Home Investire Azioni U.S.A. NASDAQ Soligenix Inc (SNGX) Soligenix Inc (SNGX) Notizie

Soligenix Inc

SNGX
0,418
0,0135 (3,34%)
04 Mag 2024 - Chiuso
Dati in Delay di 15 minuti
Borsa: NASDAQ
Tipo: Azione
Valuta: USD

Ultime notizie

Data Ora Fonte Titolo
25/4/202413:30PRNUSSoligenix Extends Patent Protection for its Filovirus..
18/4/202414:30PRNUSSoligenix Announces Pricing of $4.75 Million Public Offering
15/4/202413:30PRNUSFDA Grants Soligenix Orphan Drug Designation for the..
11/4/202413:30PRNUSFDA Grants Soligenix Orphan Drug Designation for the..
03/4/202413:30PRNUSSoligenix Announces Agreement on the Design of a Second..
15/3/202412:30PRNUSSoligenix Announces Recent Accomplishments and Year End 2023..
08/2/202413:30PRNUSSoligenix Announces Formation of Behçet's Disease Medical..
25/1/202413:30PRNUSSoligenix to Present at The Microcap Conference
08/1/202413:30PRNUSFDA Grants Soligenix "Fast Track" Designation for Dusquetide..
04/1/202413:30PRNUSSoligenix Announces Top-line Results of the Phase 2a Study..
02/1/202413:30PRNUSSoligenix Announces Publication Demonstrating Complete..
22/12/202322:05EDGAR2Form 8-K - Current report
18/12/202306:15EDGAR2Form EFFECT - Notice of Effectiveness
15/12/202322:10EDGAR2Form 4 - Statement of changes in beneficial ownership of..
15/12/202322:10EDGAR2Form 4 - Statement of changes in beneficial ownership of..
15/12/202322:10EDGAR2Form 4 - Statement of changes in beneficial ownership of..
15/12/202322:10EDGAR2Form 4 - Statement of changes in beneficial ownership of..
15/12/202322:03EDGAR2Form 8-K - Current report
08/12/202323:12EDGAR2Form 4 - Statement of changes in beneficial ownership of..
08/12/202323:11EDGAR2Form 4 - Statement of changes in beneficial ownership of..
08/12/202323:10EDGAR2Form 4 - Statement of changes in beneficial ownership of..
08/12/202323:10EDGAR2Form 4 - Statement of changes in beneficial ownership of..
08/12/202322:05EDGAR2Form S-3/A - Registration statement under Securities Act of..
01/12/202313:30PRNUS"HyBryte™ Use in Early-Stage Cutaneous T-Cell Lymphoma"..
30/11/202313:30PRNUSSoligenix Receives FDA IND Clearance for Phase 2 Clinical..
17/11/202322:05EDGAR2Form 8-K - Current report
17/11/202322:00PRNUSSoligenix, Inc. Announces Adjournment of Annual Meeting,..
13/11/202322:00EDGAR2Form 10-Q - Quarterly report [Sections 13 or 15(d)]
13/11/202313:30PRNUSSoligenix Announces Recent Accomplishments And Third Quarter..
20/10/202322:05EDGAR2Form 8-K - Current report
20/10/202322:00PRNUSSoligenix, Inc. Announces Adjournment of Annual Meeting,..
17/10/202319:00EDGAR2Form DEFA14A - Additional definitive proxy soliciting..
17/10/202319:00EDGAR2Form DEFA14A - Additional definitive proxy soliciting..
16/10/202322:45EDGAR2Form DEFA14A - Additional definitive proxy soliciting..
16/10/202313:30PRNUSSoligenix to Present at The ThinkEquity Conference
13/10/202319:00EDGAR2Form DEFA14A - Additional definitive proxy soliciting..
25/9/202313:30PRNUSSoligenix Announces Achievement of Two-Year Stability with..
22/9/202322:06EDGAR2Form DEFA14A - Additional definitive proxy soliciting..
22/9/202322:05EDGAR2Form 8-K - Current report
22/9/202322:00PRNUSSoligenix, Inc. Announces Adjournment of Annual Meeting,..
15/9/202322:10EDGAR2Form DEFA14A - Additional definitive proxy soliciting..
15/9/202322:05EDGAR2Form 8-K - Current report
30/8/202322:05EDGAR2Form S-3 - Registration statement under Securities Act of..
21/8/202323:17EDGAR2Form 10-Q - Quarterly report [Sections 13 or 15(d)]
21/8/202313:30PRNUSSoligenix Announces Recent Accomplishments And Second..
14/8/202322:09EDGAR2Form NT 10-Q - Notification of inability to timely file Form..
10/8/202313:30PRNUSHyBryte™ Expanded Treatment Trial in Cutaneous T-Cell..
07/8/202322:07EDGAR2Form DEFA14A - Additional definitive proxy soliciting..
07/8/202322:05EDGAR2Form DEF 14A - Other definitive proxy statements
11/7/202313:30PRNUSSoligenix Announces Expansion of SGX302 (Synthetic..
Apertura: 0,402 Min: 0,3958 Max: 0,4297
Chiusura: 0,4045

La tua Cronologia

NASDAQ
SNGX
Soligenix
Delayed Upgrade Clock

Il sito ADVFN Italia è stato realizzato ed è gestito da PRODESFIN su licenza di ADVFN PLC.

PER CONTATTI E PUBBLICITA' CLICCA QUI

Accedendo ai servizi offerti da ADVFN, ne si accettano le condizioni generali Termini & Condizioni

ADVFN Network